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Abstract 
Background 
Regulatory risk communications are important to ensure medication safety, but their impact is poorly 
understood. The aim was to quantify the impact of United Kingdom (UK) risk communications on 
medication use and other outcomes.  
Methods 
We conducted a systematic review of studies reporting prescribing/health outcome data relevant to UK 
regulatory risk communication. Data were re-analysed using interrupted time series regression twelve 
months after each regulatory intervention. Mean changes were pooled using random-effects generic 
inverse variance examining the following subgroups: drug withdrawals; restrictions/changes in 
indications; ‘be aware’ messages without specific recommendations for action; communication via 
Direct Healthcare Practitioner Communications (DHPCs); communication via drug bulletins.  
Results 
Of 11,466 articles screened, 40 studies examining 25 UK regulatory risk communications were included. 
Product withdrawals, restriction in indications and ‘be aware’ communications were associated with 
relative mean changes of -78% (95%CI -60% to -96%), -34% (95%CI -12 to -55%) and -11% (95%CI -8% to 
-15%) in targeted drug prescribing respectively. DHPCs were associated with relative mean changes of    
-47% (95%CI -27 to -68%) compared to -13% (95%CI -6 to -20%) for drug bulletins. Of seven studies 
examining unique health outcomes related to the safety concern, risk communications were associated 
with a mean -10% (95%CI -3 to -16%) decrease in intended and a 7% (95%CI 4 to 10%) increase in 
unintended health outcomes.  
Discussion 
UK regulatory risk communications were associated with significant changes in targeted prescribing and 
potential changes in clinical outcomes. Further research is needed to systematically study the impact of 
regulatory interventions. 
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What is already known about this subject? 
 Medicine risk communications from regulatory bodies are important to ensure medication 
safety, but their impact is often poorly understood.  
 Existing studies attempting to examine impact vary in their quality and the method of analysis. 
 We re-analysed data from a systematic review of studies measuring the impact of United 
Kingdom (UK) risk communications using a common approach to synthesis and quantify their 
impact. 
What this study adds? 
 UK medicine risk communications are associated with significant changes in targeted 
prescribing, the extent of which varies by method of communication and type of regulatory 
action. 
 Direct Healthcare Practitioner Communications were associated with larger changes in targeted 
drug prescribing than communication via drug bulletins. 
 Risk communications may be associated with significant changes in intended and unintended 
health outcomes.  
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Background 
Prescribing medications is the most commonly used healthcare intervention, but is not without risk. 
Serious and fatal adverse drug reactions in hospital are common, and adverse effects of community 
prescribed medicines are the primary cause of 6.5% of hospital admissions.[1,2] Ageing populations, 
multimorbidity and guideline recommendations for more intensive control of long-term conditions like 
hypertension have driven increases in polypharmacy. The proportion of the population dispensed ten or 
more drugs tripled between 1995 and 2010, and the proportion of patients prescribed drugs with 
potentially serious drug-drug interactions doubled.[3,4] Improving the safe use of medicines requires 
multiple strategies, but a key element is the effective communication of new information about the 
safety of medicines.  
Medicine regulators including the European Medicines Agency (EMA), the United States (US) Food and 
Drug Administration (FDA) and the United Kingdom (UK) Medicines and Healthcare products Regulatory 
Agency (MHRA) are responsible for safeguarding public health through evaluating the benefit-risk 
balance of medicines, and alerting prescribers and patients to new safety information. Regulatory 
responsibility in this area was first established after the safety concerns with thalidomide emerged in 
the 1950s and 1960s, and remains critically important today, as the recent issues around the risk of 
congenital anomalies in offspring of women taking sodium valproate during pregnancy shows.[5]  
Dissemination of new safety information is primarily done via risk communications, which are intended 
to help healthcare professionals and patients make more informed decisions to minimize potentially 
avoidable harm.[6]  However, risk communications vary in their design and method of dissemination 
both within and between countries. In most countries, risk communications are disseminated in multiple 
ways from regular drug bulletins (such as Drug Safety Update in the UK), through to more urgent direct 
communications with prescribers using Direct Healthcare Practitioner Communications (DHCP) of 
various kinds. Methods of dissemination have also changed over time, with increasing use of cascaded 
central alerting systems to improve reach.[7]  
However, there are relatively few evaluations of whether regulatory risk communication achieves its 
intended effect, in terms of changing healthcare behaviour and reducing harm.[8] A previous systematic 
review examining the impact of FDA risk communications suggests that regulatory risk alerts generally 
lead to a reduction in targeted medicine use, but with some evidence of unintended changes in 
prescribing in populations not targeted by communications.[9] However, less is known about the effects 
of regulatory risk communications in other health care systems, and studies in this field show great 
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heterogeneity in study design, method of analysis and outcomes chosen.[8] The aim of this study was to 
systematically review published studies measuring the impact of UK MHRA risk communications, 
including reanalysis of published time-series data using a single methodological approach to estimate 
impact on a common scale, and examination of how impact varies with characteristics of risk 
communications. 
Methods 
A systematic review of MEDLINE, EMBASE, Scopus and the Cochrane Library was conducted using a pre-
specified search strategy (see appendix) to identify all published English language articles evaluating the 
impact of UK medicines regulatory communications up to 25th October 2017. Identified articles were 
screened by two reviewers. Reference lists and citations of included studies were searched to identify 
additional articles. The systematic review protocol was registered on PROSPERO (number 
CRD42016033621).[10]  
Eligibility criteria 
To be included in the descriptive analysis, studies had to 1) examine the impact of a UK medicines 
regulatory risk communication, and 2) provide time-series data for prescribing or clinical outcomes.  To 
be eligible for the meta-analysis, studies were required to provide sufficient data to calculate the change 
in outcome 12 months following the risk communication using segmented regression analysis. Cross 
sectional studies were excluded. 
Outcomes 
The primary outcome of interest was the rate of prescribing of the medicine targeted by the regulatory 
risk communication. Specified secondary outcomes included: rates of prescribing of substitute 
medicines; rates of prescribing of the target medicine in a non-target population (so-called ‘spillover’ 
effects) and change in intended and unintended health outcomes that were the focus of the safety 
concern. For example, for non-steroidal anti-inflammatory drugs (NSAIDs) intended and unintended 
health outcomes could include cardiovascular events and gastrointestinal bleeding respectively. 
Data extraction  
Data were extracted on type of the regulatory action defined as: withdrawal from the market; 
recommendations to change practice based on a change or restriction of indication; recommendations 
for additional monitoring; and communications to ‘be aware’ of new information without explicitly 
recommending specific action. Data were also extracted on method of dissemination (defined as either 
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direct via a ‘Dear Health Care professional Communication’ (DHPC) letter, or indirect via drug bulletins 
containing safety warnings and other messages about medications); target medicine; population; 
outcomes evaluated; analytical methods used in the original study; and year of publication.  
Data analysis 
Descriptive analysis was conducted for all studies examining the topic, type of regulatory intervention 
and risk communication, outcomes measured and method of analysis used in the original paper. For 
studies that reported at least 12 months of data post-regulatory intervention, we re-analysed the data 
using a common approach of interrupted time series (ITS) regression in order to estimate impact on the 
outcome of interest 12 months following the regulatory intervention. Time-series data were extracted 
from tables or (if no tabular data were available) from figures using Plot Digitizer v2.6.8. Segmented 
regression models were then fitted to the time-series data. For these models, the presence of 
autocorrelation was assessed using the Durbin-Watson statistic and autocorrelation function (ACF) plots 
and partial autocorrelation function (PACF) plots. When autocorrelation was observed it was managed 
by fitting a lag value and re-examining the ACF and PACF plots.[11] For all models, the date of the risk 
communication was used as the pre-specified intervention in the model.  
For each risk communication, segmented regression model coefficients were used to estimate a 
comparable measure of effect. This was the relative change in each outcome 12 months after the date 
of the risk communication, compared to that predicted by pre-interruption trends before the risk 
communication.[11] For most regulatory interventions the intended effect was a reduction in the rate of 
the outcome. For the minority where the intended effect was to increase the rate of the outcome, the 
reciprocal of the relative change at 12 months was taken in order that results could be directly 
compared as the ‘change in the intended direction’. Estimates of the relative change at 12 months were 
then pooled using a generic inverse variance method of analysis with random-effects models in Revman 
v5 grouped by the nature of the regulatory action and by method of dissemination. When multiple 
studies measured the same regulatory action and outcome using the same source population, a single 
study was selected for inclusion in the meta-analysis based upon the size of the population studied and 
duration of data, with sensitivity analyses performed substituting this with the overlapping studies that 
were included and assessed separately. For this purpose different countries within the UK were not 
considered the same source population, since risk communication impact is likely to be mediated by 
differences in NHS organisation. We excluded models with serious non-linearity due to large changes in 
trend in the pre-intervention period detected through visual inspection of plots. 
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Risk of bias 
Risk of bias was assessed using seven standard criteria for ITS analysis studies recommended by the 
Cochrane Effective Practice and Organisation of Care group.[12]  
Patient and public involvement 
No patients or members of the public were involved in the design or conduct of this study. 
Results 
Overview of studies examining the impact of UK regulatory warnings 
Of 11,466 identified articles, 40 studies examining UK medicines regulatory risk communications were 
included (supplementary figure S1).[13-52]  These 40 studies examined the impact of 25 UK regulatory 
risk communications. Twelve of the 25 risk communications recommended a restriction of or change in 
medicine indication, eight asked prescribers to ‘be aware’ of new information about safety without 
explicit recommendations for action, four related to product withdrawals, and one to both restriction of 
indication and additional monitoring (table 1 and supplementary table S1). Twenty-six of the 40 studies 
identified examined risk communication impact for only four classes of medication; namely analgesics 
including NSAIDs (ten studies), SSRI antidepressants (six), combined oral contraceptives (five) and 
antipsychotics in people with dementia (five), while the remaining 14 studies examined risk 
communications targeting nine other medication classes (table 2). No studies examined the impact of 
specialised medicines utilised only in the hospital setting.  
Of the 40 identified studies, 35 (87.5%) evaluated the impact of the risk communication on the rate of 
prescribing of the targeted drug, 26 (65.0%) evaluated the rate of prescribing of non-target (substitute) 
drugs, and 20 (50.0%) evaluated health outcomes (table 2 and supplementary table S2). Eighteen 
(45.0%) studies used ITS regression or Joinpoint regression, seven (17.5%) studies used a different 
method of regression (that did not fully account for the time-series nature of the data), nine (22.5%) 
studies used simple descriptive statistics only (that did not account for the time-series nature of the 
data) and seven (17.5%) studies used a descriptive approach without any statistical examination of 
impact.  
Impact of UK regulatory warnings on targeted drug prescribing 
Of the 35 studies describing impact on targeted drug prescribing, 24 studies examining 17 unique 
warning and populations were eligible for re-analysis to estimate the impact on targeted drug 
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prescribing 12 months following the risk communication and are the focus of the meta-analysis (table 2). 
The mean number of pre-intervention time points available for analysis was 13.5 (range 6-29). For the 
primary outcome of rate of targeted drug prescribing by the risk communication, the largest overall 
reduction in prescribing 12 months after the date of the regulatory risk communication was associated 
with product withdrawals (mean change -78%, 95%CI -60 to -96%, figure 1 and supplementary figure S2) 
(of note co-proxamol was a phased withdrawal over two years). Smaller overall reductions were seen for 
restriction of or change in indication with recommendations for action (mean change -34%, 95%CI -12 to 
-55%, figure 1) and ‘be aware’ risk communications highlighting new information but without explicit 
recommendations for changing prescribing practice (mean change -11%, 95%CI -8 to -15%, figure 1 and 
supplementary figure S3).  When stratified by method of dissemination, the mean effect on targeted 
prescribing was larger for DHPC than for drug bulletins (mean change -47% [95%CI -27 to -68%] versus    
-13% [95%CI -6 to -20%] respectively, figure 2). This difference between DHPC and drug bulletin was 
similar when analysis was restricted only to risk communications notifying of a change of or restriction in 
indication (mean change -42% [95%CI -20 to -65%] for direct letter vs. -17% [95%CI -3 to -31%] using a 
drug bulletin) (figure 2 and supplementary figures S4 and S5). 
Impact of regulatory risk communications on substitution and spillover effects on prescribing 
Twenty six studies (65%) examined impact on other types of prescribing (supplementary table S3). This 
was most commonly for substitute medicines including prescribing of other NSAIDs (n=5) and analgesics 
(n=6) for pain, other antidepressants for depression (n=5), other oral antihyperglycaemic agents for 
diabetes (n=4), and other antipsychotics for dementia (n=3). Risk communications were associated with 
a mean increase in substitute prescribing of 28% (95%CI 15 to 41%, figure 3).  
Only four studies examined spill-over effects three of which related to risk communications about SSRIs 
in children and adolescents with depression and one relating to a risk communication about vigabatrin, 
where a decrease in prescribing of fluoxetine and lamotrigine was observed respectively.  
Impact of UK regulatory warnings on health outcomes 
Of 20 studies (50%) describing health outcomes, ten studies covering seven outcomes were eligible for 
re-analysis to estimate the impact 12 months following the risk communication for: cases of co-
proxamol poisoning and deaths from suicide (for the risk communication about co-proxamol 
withdrawal), cases of hospitalisation for paracetamol poisoning (for the risk communication about the 
benefit risk of acetylcysteine in paracetamol overdose), rate of self-harm (for the risk communication 
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about SSRIs in children and adolescents), rate of abortions and of venous thromboembolism (for the risk 
communication about combined oral contraceptive pills), and rate of admissions with gastrointestinal 
bleeding or myocardial infarction (for the risk communication about the use of COX2 inhibitors). Using 
these available data, the regulatory action was associated with a decrease in intended health outcomes 
12 months following the risk communication of -10% (95%CI -3 to -16%) and an increase in unintended 
health outcomes 12 months following the risk communication of 7% (95%CI 4 to 10%) (figure 3 and 
supplementary figure S6).  
Risk of bias 
Supplementary table S3 shows the risk of bias for the included studies. Since risk communications are 
often preceded by academic or other publications reporting new risk, or have additional later actions 
implemented, most studies were considered to be at high risk of bias because of uncertainty whether 
the risk communication intervention was independent of other changes.  The results of sensitivity 
analyses substituting with other studies measuring the same regulatory action using the same source 
population was consistent with the main findings (supplementary table S4). 
Discussion 
In view of considerable heterogeneity in the analytical methods used in the original studies examining 
the impact of UK regulatory risk communications (with just over half using no statistical analysis or 
suboptimal methods not accounting for time trends) we re-analysed data from studies to measure their 
impact on a common scale (change in outcome 12 months after the risk communication). Regulatory 
interventions leading to product withdrawals, change of or restriction in indication and general ‘be 
aware’ communications were on average associated with a significant ~78%, ~34% and ~11% changes in 
targeted prescribing in the desired direction respectively at 12 months. Regulatory risk communications 
using direct letters (DHPCs) were on average associated with greater reductions in targeted prescribing 
at 12 months (~47%) compared to safety information disseminated using drug bulletins (~17%). 
Additionally, we found some evidence that risk communications led to substitutions with other drugs, to 
spillover effects of medicines not targeted by respective risk communications, and potentially to desired 
intended but also negative unintended health outcomes.  
From these data it therefore appears that on average all three types of regulatory intervention and both 
methods of dissemination studied have significant effects on targeted drug prescribing, although effect 
sizes differ. Apart from the type of warning and method of dissemination, the heterogeneity in impact 
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could also be related to multiple factors including differences in clinical context, media coverage, 
regulatory interventions occurring elsewhere in the world, and public and professional perceptions that 
some risks are particularly serious, such as in the October 1995 ‘pill scare’ and for the use of 
antidepressants in children. Variation in impact is an important feature to consider. A previous 
systematic review including articles published up to 2010 reported that DHPCs, Black Box Warnings 
and/or Public Health Advisories appeared to have similar patterns of impact, showing an effect in 56%, 
57% and 61% of included studies respectively, with no effect in 27%, 21% and 31%, respectively, or a 
mixed effect in 17%, 21% and 8%, respectively.[53] Similarly, the impact of a DHPC targeting mirabegron 
prescribing in England demonstrated significant variation in mirabegron prescribing and variation did 
not change substantively following the DHPC.[54] Our analysis provides a study-average effect of the 
impact of each type of regulatory action and risk communication. However, variation was observed 
meaning that other factors are likely to be important in determining their absolute effect although it is 
possible that relative differences in effect would remain similar. 
A strength of this study is the rigorous approach we used to try and identify all relevant published 
articles. However, it may be that not all relevant studies will be published in peer-reviewed journals that 
could result in publication bias. We noted widely varying and often inappropriate analysis methods used 
among identified studies that do not take into account baseline trends, consistent with previous 
European and US reviews.[8,9] We therefore applied a common method of re-analysis to the extracted 
data, namely ITS analysis, which is a robust quasi-experimental design to evaluate the effects of policy 
interventions.[11] A limitation of ITS regression is that it provides evidence on associations but a key 
assumption is that there is no impact from other interventions occurring around the same time (e.g. 
publication of high-profile papers which then drive a later regulatory decision, or regulatory action in 
other countries with resulting media coverage), which in part depend on the data source as not all data 
sources may be suitable.[55] We therefore considered all included studies as high risk of bias because of 
uncertainty whether the intervention was independent of other changes. A further limitation is that the 
relatively small number of studies available meant that we were unable to fully stratify the results, 
which is important since drug withdrawals (the intervention with the highest impact) are also more 
likely to be communicated by DHPC (the dissemination method with the highest impact). However, the 
observed greater impact of DHPC over drug bulletin remained even when restricting the comparison 
among studies in which the regulatory intervention recommended a change of or restriction in 
indication only, increasing our confidence in the findings. Two risk communications were sent within 12 
months relating to paroxetine and other SSRI use in children and adolescents however sensitivity 
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analysis excluding this study from the meta-analysis had no significant impact on the effect estimates. 
Changes in prescribing outcomes for risk communications recommending additional monitoring alone 
would likely represent an unintended effect. However, only one study where the risk communication 
recommended additional monitoring was identified and this also involved a restriction in indication. As 
such, there appears to be limited studies evaluating the impact of additional monitoring 
recommendations in the UK. Safety decisions taken centrally by member states through the EMA are 
still disseminated by national competent authorities. However, information about EMA decisions may 
have been publicized a short time before a formal risk communication emerges. Finally, studies were 
relatively focused on important but narrow groups of medicines that could impact on the 
generalisability of results, with a preponderance of studies that examined medicines of wide interest 
(such as antidepressants) and a clear lack of studies examining specialised medicines used only in the 
hospitals settings. 
A previous systematic review of studies examining the impact of US FDA regulatory interventions 
reported that communications with recommendations for greater monitoring did not appear to change 
practice much, and that changes in prescribing were greater in new (incident) medication users 
compared to continuing (prevalent) users.[9] As with this review, studies in other contexts have most 
commonly evaluated use of the medicines directly targeted by the regulatory intervention and risk 
communication.[8,9] Changes in targeted drug prescribing provide an important measure of impact, but 
the primary aim of pharmacovigilance is in fact to safeguard public health and reduce harm in terms of 
clinical outcomes related to the targeted drug. Whilst clinical outcomes were only rarely evaluated in 
studies included in previous reviews [8,9] and in this review, we noted that few studies measured 
potentially harmful unintended consequences that may occur. In this regard, a balanced accounting of 
desired and undesired outcomes is generally lacking. 
Regulatory risk communication likely has variable effects because it is a complex intervention in a 
complex system and the wider health service context may modify the effect of regulatory risk 
communications that can occur between countries.[56] Antipsychotic prescribing in dementia is an 
example of this where in England, antipsychotic prescribing also declined in 2007 in the absence of any 
risk communication, shortly after the publication of National Institute of Health and Care Excellence 
(NICE) guidance for England and Wales in late 2006.[32] Substitution or spillover effects may also have 
their own unintended consequences which may reduce or negate the overall net-benefit of regulatory 
decisions and risk communications, and commonly occur.[57] 
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Although medicines regulators have made considerable effort to improve their risk communications, 
there has been little systematic research into how best to design and disseminate them. Similarly, 
regulators like EMA have developed strategies for measuring the impact of pharmacovigilance. [58] The 
decision for how certain types of information are communicated are made by committees and can be 
complex, being made by the MHRA for nationally authorised medicines or the EMA for centrally 
authorised medicines and some nationally authorised ones. These could be based upon the strength of 
evidence, the perceived importance of the safety concern, and how likely patients and healthcare 
professionals are likely to become aware of such risks without specific notifications. Unlike the nature of 
the risk warning, dissemination methods may have changed over time with increasing use of email and 
social media that potentially impacts on the speed on knowledge transfer. However, there has been 
limited robust evaluation of whether previous or new risk communication methods are effective, and if 
so how effective. For example, although a safety review conducted by the EMA in 2014 recommended 
measures to better inform women about the risk of congenital anomalies associated with use of 
valproate during pregnancy, and not to start treatment unless other options were ineffective or could 
not be tolerated, a subsequent review was undertaken by the EMA in 2018 because of concerns that 
these measures had not been sufficiently effective.  
It is not feasible to randomise clinicians or organisations to not receive any risk communication, but 
since risk communications are disseminated nationwide, it is straightforward to conceive of trials of 
‘enhanced’ compared to ‘current’ risk communication. There are a number of plausibly effective 
improvements to risk communication design that could be developed and evaluated, such as more 
systematic design of risk communications (for example, giving explicit recommendations for alternative 
action [59] or using health psychology principles to develop more persuasive or action-orientated 
communications [60]), and ensuring that risk communications come from regulators not pharmaceutical 
companies to increase their persuasiveness.[61] Similarly, plausibly effective changes to dissemination 
methods include communicating with prescribers in ways they prefer (UK GPs for example prefer point-
of-care alerts and e-mails over electronic communication via mobile apps, text messages or social media 
[56]), as well as reinforcing messages over time, for example by giving prescribers and organisations 
feedback about their use of targeted medicines.[62]. Finally, evaluation of informatics support tools to 
facilitate identification and review of patients could be worthwhile.[63] 
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Conclusion 
Despite the public health importance of pharmacovigilance systems, we found that the literature 
evaluating the impact of UK risk communications was relatively sparse, narrowly focused on a few 
medicines and risk communications, did not target specialised medicines used only in the hospital 
setting and had serious methodological weaknesses, with around half of studies using inadequate 
analytical methods. Medicines regulatory risk communications in the UK were associated with significant 
changes in targeted prescribing with some evidence of changes in clinical health outcomes, with 
communication using DHPCs associated with greater change compared with drug bulletins. 
Collaborative development and evaluation of new forms of risk communication by regulators, health 
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Figure legends 
Figure 1. Impact at 12 months on prescribing of the targeted drug stratified by type of regulatory 
action communicated by the risk communication. 
a. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS1. 
b. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS2. 
 
Figure 2. Impact at 12 months on prescribing of the targeted drug stratified by method of 
dissemination. 
a. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS1. 
b. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS2. 
 
Figure 3. Impact at 12 months on substitute prescribing and health outcomes 
a) Sandilands 2008 ANALGESIC1. Bedson 2013 ANALGESIC1. Guthrie 2013 ANTIPSYCHOTICS1. Leal 2012 DIABETES1. Wheeler 
2009 NSAID1. Watson 2007 HRT1. Mt-Isla 2015 CISAPRIDE. Stocks 2017 ANTIPSYCHOTICS1. 
b) Intended: Farmer 2000=venous thromboembolisms COCP. Narayan 2015=hospital admissions for paracetamol poisoning 
(reciprocal value) ANALGESIC2. Hawton 2012=suicides ANALGESIC1. Wheeler 2009=myocardial infarction NSAID1. 
Unintended: Shickle 2000=abortions COCP. Wheeler 2008= episodes of self-harm DEPRESSION1. Wheeler 
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Table 1. Characteristics of UK regulatory interventions and risk communication within included studies. 
Code Risk communication description (date) Nature of the warning Dissemination  
method 
Analgesics 
ANALGESIC1 Co-proxamol withdrawal (01/2005)s1 Withdrawal Direct Letter 
ANALGESIC2 Benefit risk of acetylcysteine in paracetamol overdose (09/2012)s2 Change of indication Direct Letter 
Antidepressants 
DEPRESSION1 Contraindication of Paroxetine in Children and Adolescents for depression (06/2003)s3 Restriction to indication Direct Letter 
DEPRESSION2 SSRIs: advice relating to major depressive disorder in children and adolescents (12/2003)s4 Restriction to indication Drug bulletin 
Antidiabetics 
DIABETES1 Rosiglitazone and pioglitazone: CVS safety and fracture risk (10/2007)s5 Restriction to  indication Drug bulletin 
DIABETES2 Rosiglitazone withdrawal (10/2010)s6 Withdrawal Direct Letter 
Antipsychotics 
PSYCHIATRY1 Atypical antipsychotics and risk of stroke (03/2004)s7 Restriction to indication Direct Letter 
PSYCHIATRY2 Antipsychotics: use in elderly with dementia (03/2009)s8 Be aware Drug bulletin 
PSYCHIATRY3 Typical antipsychotics: increased mortality in dementia (12/2008)s9 Be aware Drug bulletin 
PSYCHIATRY4 Antipsychotics: initiative to reduce prescribing to older people with dementia (05/2012)s10 Be aware Drug bulletin 
Hormone Replacement Therapy 
HRT1 Safety update on long-term HRT (10/2002)s11 Restriction to indication Drug bulletin 
HRT2 Safety update on long-term HRT (12/2003)s12 Restriction to indication Drug bulletin 
Non-steroidal anti-inflammatory drugs 
NSAID1 Rofecoxib withdrawal (09/2004)s13 Withdrawal Direct Letter 
NSAID2 Advice on the use of selective COX-2 and CVS safety (12/2004)s14 Restriction to  indication Direct Letter 
NSAID3 Updated advice on selective COX-2 inhibitor safety (02/2005)s15 Be aware Direct Letter 
NSAID4 Review of evidence on CVS safety of NSAIDs (08/2005)s16 Be aware Direct Letter 
NSAID5 Safety of Selective and non-selective NSAIDs (10/2006)s17 Be aware Direct Letter 
Combined Oral Contraceptive Pill 
COCP New advice on oral contraception (10/1995)s18 Be aware Direct Letter 
Others 
ASPIRIN1 Use of aspirin in children <12 years of age (06/1986)s19 Restriction to  indication Direct Letter 
VIGABATRIN1 Vigabatrin: visual field defects (11/1999)s20 Restriction to indication/additional monitoring Drug bulletin 
CISAPRIDE1 Cisapride withdrawal (07/2000)s21 Withdrawal Direct Letter 
DOSULEPIN1 Dosulepin: measures to reduce fatal overdoses (12/2007)s22 Restriction to indication Drug bulletin 
MIDAZOLAM1 Reducing risk of overdose with midazolam injections in adults (06/2009)s23 Restriction to indication Direct Letter 
CLOPIDOGREL1 Clopidogrel and proton pump inhibitors: interaction (07/2009)s24 Be aware Drug bulletin 
QUININE1 Quinine: not to be used routinely for nocturnal leg cramps (06/2010)s25 Restriction to  indication Drug bulletin 
Risk communication references = supplementary references s1-s25 in supplementary material. SSRIs=Selective serotonin reuptake inhibitors. CVS=cardiovascular. HRT=Hormone replacement therapy. COX=cyclo-
oxygenase enzyme. NSAID=non-steroidal anti-inflammatory drug. 
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Table 2. Characteristics of impact studies identified by the systematic review. 
  Behaviour change   











Sandilands 200813 ANALGESIC1 X X X Descriptive with simple statistics X 
Hawton 200914 ANALGESIC1 X X X Interrupted time series regression X 
Waring 201115 ANALGESIC1 X X - Descriptive without statistics X 
Hawton 201116 ANALGESIC1 - - X Interrupted time series regression X 
Hawton 201217 ANALGESIC1 X X X Interrupted time series regression X 
Bedson 201318 ANALGESIC1 X X - Joinpoint regression X 
Bateman 201419 ANALGESIC2 X - X Descriptive with simple statistics X 
Narayan 201520 ANALGESIC2 - - X Interrupted time series regression X 
Antidepressants  
Martin 200521 DEPRESSION1 X X - Joinpoint regression X 
Murray 200522 DEPRESSION2 X X - Descriptive with simple statistics - 
Wheeler 200823 DEPRESSION1  
DEPRESSION2 
X - X Joinpoint regression X 
Bergen 200924 DEPRESSION2 X X X Interrupted time series regression X 
Wijlaars 201225 DEPRESSION1  
DEPRESSION2 
X X - Interrupted time series regression X 
Hernandez 201226 DEPRESSION2 X X - Interrupted time series regression - 
Antidiabetics  
Leal 201227 DIABETES1 X X - Descriptive with simple statistics X 
George 200928 DIABETES1 X X - Descriptive without statistics - 
Hall 201129 DIABETES1 X X - Descriptive with logistic regression - 
Morgan 201430 DIABETES2 X X X Descriptive with Cox regression - 
Antipsychotics  
Guthrie 201331 PSYCHIATRY1  
PSYCHIATRY2 
X X - Interrupted time series regression X 
Stocks 201732 PSYCHIATRY1  
PSYCHIATRY2 
PSYCHIATRY4 
X X - Interrupted time series regression 
before and after study 
X 
Sultana 201633 PSYCHIATRY1  
PSYCHIATRY2 
X X - Generalized linear models X 
Thomas 201334 PSYCHIATRY3 X X - Interrupted time series regression X 
McIlroy 201435 PSYCHIATRY2 X - - Interrupted time series regression X 
Hormone Replacement Therapy  
Watson 200736 HRT1 HRT2 X X - Descriptive without statistics X 
Martin 201037 HRT1 X - X Joinpoint regression X 
Sharpe 201038 HRT1 X - X Change point regression X 
Non-steroidal anti-inflammatory drugs  
Williams 200639 NSAID1 X X - Descriptive without statistics - 
Wheeler 200940 NSAID1 NSAID2 X X X Joinpoint regression X 
Bedson 201318 NSAID2 NSAID3  
NSAID4 NSAID5 
X X - Joinpoint regression X 
Combined Oral Contraceptive Pill  
Farmer 200041 COCP1 - - X Descriptive with simple statistics X 
Shickle 200042 COCP1 - - X Descriptive without statistics X 
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Wood 199743 COCP1 X - X Descriptive without statistics - 
Flett 199844 COCP1 X - X Descriptive with simple statistics - 
Furedi 199945 COCP1 - - X Descriptive without statistics - 
Others       
Porter 199046 ASPIRIN1 - - X Descriptive with simple statistics - 
Ackers 200747 VIGABATRIN1 X X - Descriptive with simple statistics - 
Mt-Isa 201548 CISAPRIDE1 X X - Descriptive with Poisson regression X 
Deslandes 201649 DOSULEPIN1 X - - ARIMA model X 
Acheampong 201350 QUININE1 X - X Joinpoint regression X 
Thomas 201351 CLOPIDOGREL1 X X - Binary logistic regression  - 
Flood 201552 MIDAZOLAM1 X X X Descriptive with simple statistics - 
Bedson 2013 appears twice. Studies were not included in the meta-analysis because they did not provide data to assess impact at 12 months 
apart from Porter 1990 and Ackers 2007 were models demonstrated non-linearity due to large changes in trend in the pre-intervention period. 
ARIMA=Autoregressive Integrated Moving Average 
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Figure 1. Impact at 12 months on prescribing of the targeted drug stratified by type of regulatory 
action communicated by the risk communication. 
a. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS1. 
b. Guthrie 2013 and Stocks 2017 related to ANTIPSYCHOTICS2. 
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Figure 2. Impact at 12 months on prescribing of the targeted drug stratified by method of 
dissemination. 
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Figure 3. Impact at 12 months on substitute prescribing and health outcomes. 
